Schonfeld Strategic Advisors LLC Sells 336,631 Shares of Pfizer Inc. (NYSE:PFE)

Schonfeld Strategic Advisors LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 82.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 70,497 shares of the biopharmaceutical company's stock after selling 336,631 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Pfizer were worth $1,870,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Nordea Investment Management AB raised its stake in shares of Pfizer by 36.1% during the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after purchasing an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI raised its position in shares of Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after buying an additional 159,984 shares in the last quarter. Mcdonald Partners LLC lifted its stake in shares of Pfizer by 9.9% in the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after acquiring an additional 9,963 shares during the period. Merit Financial Group LLC boosted its holdings in shares of Pfizer by 60.8% in the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock valued at $3,395,000 after acquiring an additional 48,397 shares in the last quarter. Finally, Pensionfund Sabic boosted its holdings in shares of Pfizer by 41.7% in the fourth quarter. Pensionfund Sabic now owns 85,000 shares of the biopharmaceutical company's stock valued at $2,255,000 after acquiring an additional 25,000 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 0.5 %

Shares of NYSE:PFE traded down $0.10 during mid-day trading on Wednesday, hitting $22.78. The stock had a trading volume of 48,160,808 shares, compared to its average volume of 40,526,590. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market cap of $129.18 billion, a PE ratio of 16.15, a P/E/G ratio of 0.64 and a beta of 0.58. The company's 50 day moving average is $24.22 and its 200-day moving average is $25.67.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was down 7.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.82 earnings per share. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.55%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is currently 124.64%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PFE shares. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.